Biotech News

SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024

Sophia Genetics (SOPH)Sophia GeneticsEarnings

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full-year 2023 before U.S. markets open on Tuesday, March 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.

The call will be webcast live on the SOPHiA GENETICS Investor Relations website . Additionally, a replay will be available on the website after its completion.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products, and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram . Where others see data, we see answers.

Related news

Sophia Genetics

AI-Native Precision-Medicine Platform SOPHiA GENETICS provides cloud-based software and analytical services that help healthcare institutions and biopharmaceutical companies interpret complex multimodal data. Its platform is used in clinical diagnostics, translational research, therapy development, and companion-diagnostic...

Recent company news

Stock data

Close
7.35 USD
Market cap
354.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States